Evidence map›Paper›PMID 35606494›Full record

ArticleGene therapy2023

Effects of intracardiac delivery of aldehyde dehydrogenase 2 gene in myocardial salvage.

Guodong Pan, Bipradas Roy, Pamela Harding, Thomas Lanigan, Roland Hilgarth, Rajarajan A Thandavarayan, Suresh Selvaraj Palaniyandi

Open access · greenAbstract read
In one paragraph

Article in Gene therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Guodong PanDivision of Hypertension and Vascular Research, Department of Internal Medicine, Henry Ford Health System, Detroit, MI, 48202, USA.
Bipradas RoyDivision of Hypertension and Vascular Research, Department of Internal Medicine, Henry Ford Health System, Detroit, MI, 48202, USA.
Pamela HardingDivision of Hypertension and Vascular Research, Department of Internal Medicine, Henry Ford Health System, Detroit, MI, 48202, USA.
Thomas LaniganVector Core, Biomedical Research Core Facilities, University of Michigan Medical School, Ann Arbor, MI, 48109, USA.
Roland HilgarthVector Core, Biomedical Research Core Facilities, University of Michigan Medical School, Ann Arbor, MI, 48109, USA.
Rajarajan A ThandavarayanDepartment of Cardiovascular Sciences, Houston Methodist Research Institute, Houston, TX, 77030, USA.
Suresh Selvaraj PalaniyandiDivision of Hypertension and Vascular Research, Department of Internal Medicine, Henry Ford Health System, Detroit, MI, 48202, USA. spalani2@hfhs.org.ORCID http://orcid.org/0000-0001-7559-8041
Henry Ford Health System · USUniversity of Michigan · USHouston Methodist · US

Funding

Regional Pilot And Feasibility Study Grants ProgramP30DK020572 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Mehboob A Hussain · 2013 to 2026
$24.3M
4-hydroxy-2-nonenal in mitochondrial DNA damage and contractile dysfunction in diabetic heart: a role for aldehyde dehydrogenase 2R01HL139877 · NHLBI · HENRY FORD HEALTH SYSTEM · PI PALANIYANDI, SURESH SELVARAJ · 2018 to 2020
$1.1M
Resolvin D1 resolves inflammation in metabolic stress associated HFpEFR21ES033813 · NIEHS · WAYNE STATE UNIVERSITY · PI PALANIYANDI, SURESH SELVARAJ · 2022 to 2023
$404k
4-hydoxy-2-nonenal in mitochondrial DNA damage and contractile dysfunction in diabetic heart: a role for aldehyde dehydrogenase 2R56HL131891 · NHLBI · HENRY FORD HEALTH SYSTEM · PI PALANIYANDI, SURESH SELVARAJ · 2017 to 2017
$375k
NHLBI NIH HHS R01 HL139877NHLBI NIH HHS R56 HL131891NIDDK NIH HHS P30 DK020572NIEHS NIH HHS R21 ES033813
6 · The paper itself

Abstract

Intrinsic activity of aldehyde dehydrogenase (ALDH)2, a cardiac mitochondrial enzyme, is vital in detoxifying 4-hydroxy-2-nonenal (4HNE) like cellular reactive carbonyl species (RCS) and thereby conferring cardiac protection against pathological stress. It was also known that a single point mutation (E487K) in ALDH2 (prevalent in East Asians) known as ALDH2*2 reduces its activity intrinsically and was associated with increased cardiovascular diseases. We and others have shown that ALDH2 activity is reduced in several pathologies in WT animals as well. Thus, exogenous augmentation of ALDH2 activity is a good strategy to protect the myocardium from pathologies. In this study, we will test the efficacy of intracardiac injections of the ALDH2 gene in mice. We injected both wild type (WT) and ALDH2*2 knock-in mutant mice with ALDH2 constructs, AAv9-cTNT-hALDH2-HA tag-P2A-eGFP or their control constructs, AAv9-cTNT-eGFP. We found that intracardiac ALDH2 gene transfer increased myocardial levels of ALDH2 compared to GFP alone after 1 and 3 weeks. When we subjected the hearts of these mice to 30 min global ischemia and 90 min reperfusion (I-R) using the Langendorff perfusion system, we found reduced infarct size in the hearts of mice with ALDH2 gene vs GFP alone. A single time injection has shown increased myocardial ALDH2 activity for at least 3 weeks and reduced myocardial 4HNE adducts and infarct size along with increased contractile function of the hearts while subjected to I-R. Thus, ALDH2 overexpression protected the myocardium from I-R injury by reducing 4HNE protein adducts implicating increased 4HNE detoxification by ALDH2. In conclusion, intracardiac ALDH2 gene transfer is an effective strategy to protect the myocardium from pathological insults.

Indexed as

MyocardiumPoint MutationAldehyde Dehydrogenase, MitochondrialAnimalsInfarctionMiceMitochondriaAldehyde Dehydrogenase, Mitochondrial

Identifiers

PMID35606494
PMCPMC9684354
OpenAlexW4281392954

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.